These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28277798)

  • 21. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials.
    Catapano AL; Lee LV; Louie MJ; Thompson D; Bergeron J; Krempf M
    Sci Rep; 2017 Apr; 7():45788. PubMed ID: 28374849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.
    Qian LJ; Gao Y; Zhang YM; Chu M; Yao J; Xu D
    Sci Rep; 2017 Mar; 7(1):238. PubMed ID: 28331223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges.
    Rashid H; Meredith IT; Nasis A
    Heart Lung Circ; 2017 Aug; 26(8):786-798. PubMed ID: 28286091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.
    Cicero AFG; Bove M; Borghi C
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):9-15. PubMed ID: 29231064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidrug Antibodies in Patients Treated with Alirocumab.
    Roth EM; Goldberg AC; Catapano AL; Torri A; Yancopoulos GD; Stahl N; Brunet A; Lecorps G; Colhoun HM
    N Engl J Med; 2017 Apr; 376(16):1589-90. PubMed ID: 28304229
    [No Abstract]   [Full Text] [Related]  

  • 26. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
    Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ
    BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.
    Li S; Guo YL; Zhao X; Zhang Y; Zhu CG; Wu NQ; Xu RX; Qing P; Gao Y; Li XL; Sun J; Liu G; Dong Q; Li JJ
    Sci Rep; 2017 Mar; 7(1):360. PubMed ID: 28336922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS
    Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.
    Zhu Y; Shen X; Jiang Q; Wang Z; Wang Z; Dong X; Li J; Han Q; Zhao J; Wang B; Liu L
    Herz; 2019 Jun; 44(4):336-346. PubMed ID: 29116337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein(a): the revenant.
    Gencer B; Kronenberg F; Stroes ES; Mach F
    Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.
    Baruch A; Luca D; Kahn RS; Cowan KJ; Leabman M; Budha NR; Chiu CPC; Wu Y; Kirchhofer D; Peterson A; Davis JC; Tingley WG
    Clin Cardiol; 2017 Jul; 40(7):503-511. PubMed ID: 28326559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current status of lipid management in acute coronary syndrome.
    Fujisue K; Tsujita K
    J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females.
    Hasan H; Attlee A; Raigangar V; Madkour M; Awadallah S
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S337-S341. PubMed ID: 28283395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Leiter LA; Cariou B; Müller-Wieland D; Colhoun HM; Del Prato S; Tinahones FJ; Ray KK; Bujas-Bobanovic M; Domenger C; Mandel J; Samuel R; Henry RR
    Diabetes Obes Metab; 2017 Dec; 19(12):1781-1792. PubMed ID: 28905478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).
    Baruch A; Mosesova S; Davis JD; Budha N; Vilimovskij A; Kahn R; Peng K; Cowan KJ; Harris LP; Gelzleichter T; Lehrer J; Davis JC; Tingley WG
    Am J Cardiol; 2017 May; 119(10):1576-1583. PubMed ID: 28343601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis.
    He XX; Zhang R; Zuo PY; Liu YW; Zha XN; Shan SS; Liu CY
    Eur J Intern Med; 2017 Mar; 38():52-60. PubMed ID: 28341307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection.
    Tatlock S; Arbuckle R; Sanchez R; Grant L; Khan I; Manvelian G; Spertus JA
    Value Health; 2017 Mar; 20(3):430-440. PubMed ID: 28292488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezetimibe Increases Endogenous Cholesterol Excretion in Humans.
    Lin X; Racette SB; Ma L; Wallendorf M; Ostlund RE
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):990-996. PubMed ID: 28279967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.